China Pharma Holdings Inc. (CPHI) is a publicly traded biopharmaceutical company. Established in 1999 and headquartered in Haikou City, Hainan Province, China, CPHI specializes in the development, manufacturing, and marketing of a diversified portfolio of proprietary healthcare and pharmaceutical products.
Part of the rapidly growing pharmaceutical industry in China, CPHI operates through its wholly-owned Chinese subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. They are engaged in the research, production, and sale of both Over-The-Counter (OTC) medicines and prescription-based pharmaceutical products. This wide-ranging portfolio includes treatments for various types of diseases such as rheumatism, respiratory and cardiovascular diseases, infections, skin diseases, and cerebrovascular diseases among others.
CPHI has a comprehensive sales and distribution network that covers more than 30 provinces, municipalities, and autonomous regions throughout China, ensuring that its products reach the massive and potential-rich medical market in the country. As of 2020, the company's product list comprises more than 20 different types of pharmaceutical products marketed under recognized brand names, and it continues to focus on new product development to maintain its competitive edge.
The company's infrastructure is composed of modern facilities designed according to Good Manufacturing Practices (GMP), following international and domestic standards for quality assurance. Through these facilities, CPHI targets the growing demand for improved healthcare treatments resulting from increased living standards and aging Chinese population.
To remain at the forefront of R&D, China Pharma Holdings has invested heavily in its research and development facilities, constantly driving progress in both existing and new business areas. Their long-term development strategy includes maintaining a sustainable product pipeline, enhancing research capacity, and pursuing strategic alliances and cooperation, among others.
Over the years, CPHI has displayed a resilient business model, proving itself capable of dealing with the many challenges and opportunities presented by the rapidly evolving Chinese healthcare sector. As it seeks to continuously expand its market reach and product range, China Pharma Holdings, Inc. promises to play an increasingly significant role in addressing the diverse healthcare needs of the Chinese population.